Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | NR1H4 | Q96RI1 | 14/20 | 0.40 |
| ▸ | VDR | P11473 | 5/20 | 0.40 |
| ▸ | PKM | P14618 | 2/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 4/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.37 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.36 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL5513157 | 0.99 | L3MBTL1 (0.40) | L3MBTL1NR1H4VDRPKMSMN1; SMN2 | |
| SCHEMBL6699127 | 0.95 | L3MBTL1 (0.43) | L3MBTL1NR1H4VDRPKMSMN1; SMN2 | |
| SCHEMBL6700818 | 0.95 | L3MBTL1 (0.43) | L3MBTL1NR1H4VDRPKMSMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL5515021 | 0.94 | L3MBTL1 (0.42) | L3MBTL1NR1H4VDRPKMSMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL5512627 | 0.94 | L3MBTL1 (0.42) | L3MBTL1NR1H4VDRPKMSMN1; SMN2 | |
| SCHEMBL6700684 | 0.93 | L3MBTL1 (0.41) | L3MBTL1NR1H4VDRPKMSMN1; SMN2 | |
| SCHEMBL6700695 | 0.92 | NR1H4 (0.41) | L3MBTL1NR1H4VDRPKMSMN1; SMN2 | |
| SCHEMBL12204670 | 0.92 | L3MBTL1 (0.42) | L3MBTL1NR1H4VDRPKMSMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL5513868 | 0.92 | L3MBTL1 (0.41) | L3MBTL1NR1H4VDRPKMSMN1; SMN2 | |
| SCHEMBL14383819 | 0.92 | L3MBTL1 (0.40) | L3MBTL1NR1H4VDRPKMSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040082635-A1 | Viricide against hepatitis virus; polymerase inhibitor | JAPAN TOBACCO INC. (JP) | 2004-04-29 | — | — | US | claimed |
| EP-1400241-A1 | FUSED CYCLIC COMPOUNDS AND MEDICINAL USE THEREOF | JAPAN TOBACCO INC. (JP) | 2004-03-24 | — | — | EP | claimed |
| US-7285551-B2 | Fused-ring compounds and use thereof as drugs | JAPAN TOBACCO INC. (JP) | 2007-10-23 | — | — | US | disclosed |
| US-7285551-B2 | Fused-ring compounds and use thereof as drugs | JAPAN TOBACCO INC. (JP) | 2007-10-23 | — | — | US | disclosed |
| US-20040082635-A1 | Viricide against hepatitis virus; polymerase inhibitor | JAPAN TOBACCO INC. (JP) | 2004-04-29 | — | — | US | disclosed |
| EP-1400241-A1 | FUSED CYCLIC COMPOUNDS AND MEDICINAL USE THEREOF | JAPAN TOBACCO INC. (JP) | 2004-03-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040082635-A1 | Viricide against hepatitis virus; polymerase inhibitor | HAVCR2, ZC3HAV1, POLR1C | L3MBTL1 3799/4885NR1H4 484/4885VDR 3852/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.